Shots: The P-III YOSEMITE & RHINE studies involve assessing faricimab (6mg at personalized dosing intervals of up to 4mos. and at fixed 2mos. intervals) vs aflibercept (2mg, fixed 2mos. intervals) […]readmore
Tags : Age-Related Macular Degeneration
Shots: SERI and Gemini will investigate the link b/w genetic & potential biomarkers in patients with PCV. The collaboration leverages Gemini’s experience of precision medicine to develop therapies targeting the […]readmore
Shots: The EC’s approval is based on P-III HAWK (6/3mg) & HARRIER (6mg) study assessing Beovu [q12w/q8w with the majority on q12w following the loading phase) vs aflibercept 2 mg […]readmore
Shots: OliX to receive $2.27M upfront, clinical milestones and royalties on sales of product. Thea to get license rights to develop & commercialize OLX301A in EU, Middle East and Africa […]readmore